English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

C ancer is still the second leading cause of death in the United States and earlier diagnosis and efective therapies remain the holy grail of research paradigms. Cancer biomarkers have emerged as an invaluable tool in the achievement of this goal. Technological advancements and greater understanding of the molecular mechanisms of cancer have transformed biomarker research from an observational byproduct of cancer research into a biomedical research feld in its own right. Despite the explosion of biomarker discovery over the last decade, few have been translated into clinical use. Here we discuss the current state of biomarker development and the challenges that have tempered their clinical potential.

Delivering on the promise of cancer biomarkers in the clinic